Caris Life Sciences (CAI) Shares Outstanding (2024 - 2026)
Caris Life Sciences (CAI) posted quarterly Shares Outstanding (Entity) of $284.3 million for Q1 2026, up 706.7% year-over-year from $35.2 million in Q1 2025, and up 70.01% quarter-over-quarter from $167.2 million in Q4 2025.
Caris Life Sciences (CAI) Shares Outstanding (2024 - 2026) Analysis & Trends
Caris Life Sciences' Shares Outstanding (Entity) history runs 3 years deep, the most recent figure standing at $284.3 million for Q1 2026.
- In Q1 2026, Shares Outstanding (Entity) rose 706.7% year-over-year to $284.3 million; the TTM figure through Mar 2026 stood at $284.3 million (up 706.7% YoY), while the FY2025 annual figure was $167.2 million, up 355.76% from the prior year.
- Shares Outstanding (Entity) for Q1 2026 stood at $284.3 million, up from $167.2 million in the prior quarter.
- The five-year high for Shares Outstanding (Entity) was $284.3 million in Q1 2026, with the low at $35.2 million in Q1 2025.
- The 3-year median for Shares Outstanding (Entity) is $50.8 million (2024), against an average of $117.9 million.
- The sharpest annual moves came in 2025 and 2026: Shares Outstanding (Entity) jumped 83.29% in 2025, then soared 706.7% in 2026.
- Caris Life Sciences' Shares Outstanding (Entity) stood at $36.7 million in 2024, then surged by 355.76% to $167.2 million in 2025, then jumped by 70.01% to $284.3 million in 2026.
- Business Quant data shows CAI's Shares Outstanding (Entity) at $284.3 million in Q1 2026, $167.2 million in Q4 2025, and $283.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Shares Outstanding (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 253.70 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 102.80 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 62.19 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 210.89 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.45 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 25.05 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 445.06 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 133.61 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 217.35 Mn |
| 10 | Caris Life Sciences | 6.16 Bn | 5.37 Bn | 182.38 Mn | 282.89 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 282.89 Mn |
| Mar 31, 2026 | 282.56 Mn |
| Dec 31, 2025 | 167.21 Mn |
| Sep 30, 2025 | 282.10 Mn |
| Jun 30, 2025 | 64.92 Mn |
| Mar 31, 2025 | 35.62 Mn |
| Dec 31, 2024 | 35.50 Mn |
| Sep 30, 2024 | 35.64 Mn |
| Jun 30, 2024 | 35.37 Mn |